Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

@article{Savvides2013PhaseIT,
  title={Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.},
  author={Panayiotis Panos Savvides and Govardhanan Nagaiah and Pierre N Lavertu and Pingfu Fu and John Joseph Wright and Robert A. Chapman and Jay K Wasman and Afshin Dowlati and Scot C. Remick},
  journal={Thyroid : official journal of the American Thyroid Association},
  year={2013},
  volume={23 5},
  pages={600-4}
}
BACKGROUND Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3-5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models, sorafenib inhibits the growth of ATC xenografts and improves survival. No study of sorafenib in ATC has been conducted. We conducted a multi-institutional phase II trial of sorafenib… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…